CCR2 and neoplasm: Finally, it was confirmed in the patient-derived tumor xenograft (PDTX) model that its binding with CCR2 on the surface of tumor cells can promote CCR2b-B7-H3-CAR-T cells to penetrate the blood–brain barrier.